Today’s Research Reports on Stocks to Watch: Loxo Oncology and Boston Scientific

NEW YORK, NY / ACCESSWIRE / April 5, 2018 / Shares of Loxo Oncology were gaining heavily in Wednesday trading after the company announced that it would be presenting interim results of its Phase 1 clinical trial of LOXO-292, a cancer drug candidate. Shares of Boston Scientific also sailed higher as Wall Street digested the company’s announcement this week about acquiring Securus Medical.

RDI Initiates Coverage on:

Loxo Oncology, Inc.
https://rdinvesting.com/report/?ticker=LOXO

Boston Scientific Corporation
https://rdinvesting.com/report/?ticker=BSX

Loxo Oncology, Inc. shares closed up about 10% on Wednesday with slightly higher trading volume than usual at around 500,000 shares traded. The biopharma company announced yesterday that interim clinical data from the company’s ongoing Phase 1 clinical trial of LOXO-292, will be presented this June at the American Society of Clinical Oncology Annual Meeting. The meeting is held on June 1st through the 5th and Loxo’s presentation is called, “A Phase 1 Study of LOXO-292, A Potent and Highly Selective RET Inhibitor, in Patients with RET-Altered Cancers.” LOXO-292 is the company’s drug candidate for the treatment of patients with cancers that harbor abnormalities in the rearranged during transfection (RET) kinase. Loxo has a focus on highly selective medicines for patients with genetically defined cancers.

Access RDI’s Loxo Oncology, Inc. Research Report at:
https://rdinvesting.com/report/?ticker=LOXO

Boston Scientific Corporation shares closed up 1.02% on about 7.7 million shares traded on Wednesday. On Tuesday the company announced that it has acquired Securus Medical, an Ohio-based privately-held company that has developed a thermal monitoring system for esophageal temperature measurement on a continuous basis. The system ensures that heart tissue triggering arrhythmia is not damaged during cardiac ablation procedures. Boston Scientific first took a stake in the company back in 2016 and is buying the remainder of stake now. The company has paid an upfront cash payment of $40 million and as part of the deal, there are also commercial milestones and regulatory achievement based contingent payments that can fetch as much as $10 million. Boston Scientific president, Joe Fitzgerald, remarked, “The acquisition of Securus further broadens our electrophysiology portfolio and fuels our mission to provide physicians with meaningful innovations that advance patient care.” Steven Girouard, president and chief executive officer of Securus Medical Group, commented, “In contrast to current standards of care for esophageal temperature monitoring that measure temperature at one or a few fixed locations and have a slow temporal response, this system continuously reads the temperature of the esophagus from thousands of points and provides physicians with an intuitive 360-degree view that refreshes every second.”

Access RDI’s Boston Scientific Corporation Research Report at:
https://rdinvesting.com/report/?ticker=BSX

Our Actionable Research on Loxo Oncology, Inc. (NASDAQ: LOXO) and Boston Scientific Corporation (NYSE: BSX) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 495219